A randomised double-blind placebo-controlled 12- week feasibility trial of methotrexate added to treatment as usual in early schizophrenia: study protocol for a randomised controlled trial

BACKGROUND: Methotrexate is a commonly used anti-inflammatory and immunosuppressive drug. There is growing evidence that inflammatory processes are involved in the pathogenesis of schizophrenia. In our recent randomised double-blind placebo-controlled clinical trial in Pakistan and Brazil, the addit...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaudhry, Imran B, Husain, Nusrat, ur Rahman, Raza, Husain, Mohammed Omair, Hamirani, Mohammed M, Kazmi, Ajmal, Baig, Shakeel, Haddad, Peter M, Buch, Maya H, Qureshi, Inti, Mehmood, Nasir, Kiran, Tayyeba, Fu, Bo, Afsar, Salahuddin, Deakin, Bill
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326487/
https://www.ncbi.nlm.nih.gov/pubmed/25563714
http://dx.doi.org/10.1186/1745-6215-16-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326487/
https://www.ncbi.nlm.nih.gov/pubmed/25563714
http://dx.doi.org/10.1186/1745-6215-16-9

Ejemplares similares